Phase III RUXCOVID study of ruxolitinib (Jakafi®) as a treatment for COVID-19 associated cytokine storm fails to meet primary endpoint

Initial data showed no difference in severe complications including death, respiratory failure requiring mechanical ventilation or admission to ICU by day 29, with ruxolitinib plus standard-of-care (SOC) vs SoC (12.0% vs. 11.8%; OR: 0.91; 95% CI: 0.48-1.73; P=0.769).

Biospace Inc.